BENEFITS OF HIGH VERSUS LOW DOSE UPADACITINIB AS MAINTENANCE TREATMENT IN ULCERATIVE COLITIS PATIENTS WHO WERE RESPONDERS TO 8-WEEK INDUCTION WITH UPADACITINIB: RESULTS FROM THE U-ACHIEVE PHASE 3 MAINTENANCE TRIAL
Brian G. Feagan 1
Gareth Parkes 2
Pascal Juillerat 3
Krisztina Barbara Gecse 4
Xuan Yao 5
Wen Zhou 6
Huiwen Deng
Dapo Ilo 7
Yuri Sanchez Gonzalez
Peter D.R. Higgins 8
1 Western University, London, Canada
2 Barts Health NHS Trust, London, United Kingdom
3 Gastroenterology, Department of Visceral Surgery and Medicine, Inselspital Bern and Bern University, Bern, Switzerland
4 Location AMC, Amsterdam UMC, Amsterdam, Netherlands
5 AbbVie Inc., North Chicago, United States
6 AbbVie, Inc., North Chicago, United States
7 AbbVie Inc., North Chicago, United Kingdom
8 University of Michigan, Ann Arbor, United States
Topic
IBD, Nurses, Primary Care
Conference
UEG Week 2022
Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]